Testing scans and biomarkers for CAR T neurotoxicity risk
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study uses blood tests and brain imaging to better understand and predict nerve-system side effects that can happen after CAR T-cell treatment. It may help doctors spot people at higher risk sooner and guide safer care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You are scheduled to receive CAR T-cell treatment
- You agree to sign the study consent form
- You have not had CAR T treatment before
- You do not have a brain bleeding risk or recent major bleeding
- You can have MRI safely (no incompatible pacemaker or implanted electrical device)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people getting CAR-T cell therapy, a type of cancer treatment that uses your own immune cells. Researchers want to understand a rare side effect called neurotoxicity by looking at tiny particles in your blood called extracellular vesicles.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
This study watches patients getting CAR-T cell therapy to see if it affects brain function, thinking, or memory. It aims to find out how common these effects are and help doctors manage them.
This study uses brain scans and blood markers to understand how CAR T-cell therapy affects the brain. It may help researchers predict or manage potential side effects.
This trial tests if a spinal injection of three common chemotherapy drugs can reduce or prevent serious brain and nerve side effects in people receiving CAR-T cell therapy for cancer.
This Phase 1 study tests a new type of immune therapy (CAR T cells) placed directly into the fluid around the brain to treat central nervous system (CNS) lymphoma. It mainly looks at safety and how well the treatment can control the lymphoma when other CNS treatments have not worked.
Hear when a new Immune Effector Cell Associated Neurotoxicity Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.